FDA Continues to Defend Zohydro Approval, State Prosecutors Criticize

Washington Drug Letter
As more critics of the FDA’s approval of the painkiller Zohydro ER come forward, the agency says it will not limit approval of new opioid painkillers to those with abuse-deterrent properties.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00